+52.4%
GEV vs MRNA
+945.0%
-892.7%
-30.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -9.3% | +13.1% | -22.4% | -9.4% |
| 7D | -5.1% | +20.6% | -25.8% | -5.4% |
| 30D | -15.8% | +27.1% | -43.0% | -16.0% |
| 3M | -18.2% | +353.4% | -371.6% | -20.9% |
| 6M | -22.4% | +446.3% | -468.6% | -28.2% |
| YTD | +27.7% | +776.2% | -748.4% | +7.8% |
| 1Y | +52.4% | +987.9% | -935.6% | +21.8% |
| All | +52.4% | +945.0% | -892.7% | +21.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling